Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1

Oncogene

Volumn 26, Issue 24, 2007, Pages 3473-3481

  Ambrosini, G ^a   Sambol, E B ^a   Carvajal, D ^b   Vassilev, L T ^b   Singer, S ^a   Schwartz, G K ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b HOFFMANN LA ROCHE INC   (United States)

Author keywords

Apoptosis; DNA damage; E2F1; MDM2; Nutlin 3a

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; MUTANT PROTEIN; NUTLIN 3A; PROTEASOME; PROTEIN INHIBITOR; PROTEIN MDM2; PROTEIN NOXA; PROTEIN P53; PROTEIN P73; PROTEIN P73ALPHA; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR E2F1; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING KINETICS; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CELL DIFFERENTIATION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOTOXICITY; DNA DAMAGE; DOWN REGULATION; DRUG DOSE SEQUENCE; DRUG POTENTIATION; DRUG SENSITIVITY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LIPOSARCOMA; MALE; MONOTHERAPY; NERVE SHEATH TUMOR; PERIPHERAL NERVE TUMOR; PRIORITY JOURNAL; REGULATORY MECHANISM; RNA INTERFERENCE; SARCOMA CELL; TRANSCRIPTION INITIATION; WILD TYPE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARBOPLATIN; CISPLATIN; DNA-BINDING PROTEINS; DOXORUBICIN; E2F1 TRANSCRIPTION FACTOR; HUMANS; IMIDAZOLES; MICE; NUCLEAR PROTEINS; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-MDM2; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 34249303144     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1210136     Document Type: Article

References (36)

1. Banerjee D, Schnieders B, Fu JZ, Adhikari D, Zhao SC, Bertino JR. (1998). Role of E2F1 in chemosensitivity. Cancer Res 58: 4292-4296.
2. Bianco R, Ciardiello F, Tortora G. (2005). Chemosensitization by antisense oligonucleotides targeting MDM2. Curr Cancer Drug Targets 5: 51-56.
3. Bond GL, Hu W, Levine AJ. (2005). MDM2 is a central node in the p53 pathway: 12 years and counting. Curr Cancer Drug Targets 5: 3-8.
4. Carvajal D, Tovar C, Yang H, Vu BT, Heimbrook DC, Vassilev LT. (2005). Activation of p53 by MDM2 antagonists can protect proliferating cells from mitotic inhibitors. Cancer Res 65: 1918-1924.
5. Dai MS, Lu H. (2004). Inhibition of MDM2-mediated p53 ubiquitination and degradation by ribosomal protein L5. J Biol Chem 279: 44475-44482.
6. Furukawa Y, Nishimura N, Furukawa Y, Satoh M, Endo H, Iwase S et al. (2002). Apaf-1 is a mediator of E2F-1-induced apoptosis. J Biol Chem 277: 39760-39768.
7. Ganguli G, Wasylyk B. (2003). p53-independent functions of MDM2. Mol Cancer Res 1: 1027-1035.
8. Hershko T, Ginsberg D. (2004). Up-regulation of Bcl-2 homology 3 (BH3)-only proteins by E2F1 mediates apoptosis. J Biol Chem 279: 8627-8634.
9. Honda R, Yasuda H. (1999). Association of p19(ARF) with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53. EMBO J 18: 22-27.
10. Huang Y, Ishiko T, Nakada S, Utsugisawa T, Kato T, Yuan ZM. (1997). Role for E2F in DNA damage-induced entry of cells into S phase. Cancer Res 57: 3640-3643.
11. Irwin M, Marin MC, Phillips AC, Seelan RS, Smith DI, Liu W et al. (2000). Role for the p53 homologue p73 in E2F-1-induced apoptosis. Nature 407: 645-648.
12. Johnson DG, Schwarz JK, Cress WD, Nevins JR. (1993). Expression of transcription factor E2F1 induces quiescent cells to enter S phase. Nature 365: 349-352.
13. Kojima K, Konopleva M, Samudio IJ, Shikami M, Cabreira-Hansen M, McQueen T et al. (2005). MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy. Blood 106: 3150-3159.
14. Kowalik TF, DeGregori J, Schwarz JK, Nevins JR. (1995). E2F1 overexpression in quiescent fibroblasts leads to induction of cellular DNA synthesis and apoptosis. J Virol 69: 2491-2500.
15. Lin WC, Lin FT, Nevins JR. (2001). Selective induction of E2F1 in response to DNA damage, mediated by ATM-dependent phosphorylation. Genes Dev 15: 1833-1844.
16. Loughran O, La Thangue NB. (2000). Apoptotic and growth-promoting activity of E2F modulated by MDM2. Mol Cell Biol 20: 2186-2197.
17. Martin K, Trouche D, Hagemeier C, Sorensen TS, La Thangue NB, Kouzarides T. (1995). Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein. Nature 375: 691-694.
18. Meng RD, Phillips P, El-Deiry WS. (1999). p53-independent increase in E2F-1 expression enhances the cytotoxic effects of etoposide and of adriamycin. Int J Oncol 14: 5-14.
19. Midgley CA, Lane DP. (1997). p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding. Oncogene 15: 1179-1189.
20. Momand J, Jung D, Wilczynski S, Niland J. (1998). The MDM2 gene amplification database. Nucleic Acids Res 26: 3453-3459.
21. Muller H, Bracken AP, Vernell R, Moroni MC, Christians F, Grassilli E et al. (2001). E2Fs regulate the expression of genes involved in differentiation, development, proliferation, and apoptosis. Genes Dev 15: 267-285.
22. Nip J, Strom DK, Fee BE, Zambetti G, Cleveland JL, Hiebert SW. (1997). E2F-1 cooperates with topoisomerase II inhibition and DNA damage to selectively augment p53-independent apoptosis. Mol Cell Biol 17: 1049-1056.
23. Pediconi N, Ianari A, Costanzo A, Belloni L, Gallo R, Cimino L et al. (2003). Differential regulation of E2F1 apoptotic target genes in response to DNA damage. Nat Cell Biol 5: 552-558.
24. Piette J, Neel H, Marechal V. (1997). Mdm2: keeping p53 under control. Oncogene 15: 1001-1010.
25. Qin XQ, Livingston DM, Kaelin Jr WG, Adams PD. (1994). Deregulated transcription factor E2F-1 expression leads to S-phase entry and p53-mediated apoptosis. Proc Natl Acad Sci USA 91: 10918-10922.
26. Stiewe T, Putzer BM. (2000). Role of the p53-homologue p73 in E2F1-induced apoptosis. Nat Genet 26: 464-469.
27. Stuhmer T, Chatterjee M, Hildebrandt M, Herrmann P, Gollasch H, Gerecke C et al. (2005). Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma. Blood 106: 3609-3617.
28. Tovar C, Rosinski J, Filipovic Z, Higgins B, Kolinsky K, Hilton H et al. (2005). Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proc Natl Acad Sci USA 103: 1888-1893.
29. Vassilev LT. (2005). p53 Activation by small molecules: application in oncology. J Med Chem 48: 4491-4499.
30. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z et al. (2004). In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303: 844-848.
31. Wasylyk C, Salvi R, Argentini M, Dureuil C, Delumeau I, Abecassis J et al. (1999). p53 mediated death of cells overexpressing MDM2 by an inhibitor of MDM2 interaction with p53. Oncogene 18: 1921-1934.
32. Wu X, Levine AJ. (1994). p53 and E2F-1 cooperate to mediate apoptosis. Proc Natl Acad Sci USA 91: 3602-3606.
33. Xiao ZX, Chen J, Levine AJ, Modjtahedi N, Xing J, Sellers WR et al. (1995). Interaction between the retino-blastoma protein and the oncoprotein MDM2. Nature 375: 694-698.
34. Yang Y, Ludwig RL, Jensen JP, Pierre SA, Medaglia MV, Davydov IV et al. (2005). Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells. Cancer Cell 7: 547-559.
35. Zeng X, Chen L, Jost CA, Maya R, Keller D, Wang X et al. (1999). MDM2 suppresses p73 function without promoting p73 degradation. Mol Cell Biol 19: 3257-3266.
36. Zhang Z, Wang H, Li M, Rayburn ER, Agrawal S, Zhang R. (2005). Stabilization of E2F1 protein by MDM2 through the E2F1 ubiquitination pathway. Oncogene 24: 7238-7247.